Cite
HARVARD Citation
Attauabi, M. et al. (2021). Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases. Scandinavian journal of gastroenterology. pp. 1040-1048. [Online].